top of page

Lung Cancer Trials

NCI-2020-00751

A081801: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

The ALCHEMIST trial focuses on adding immunotherapy to the treatment plan for non-small cell lung cancer (NSCLC) patients who have had surgery to remove their tumors. This trial, known as "Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO," aims to see if combining immunotherapy with standard chemotherapy after surgery is more effective than the usual treatment. Researchers also want to identify any markers in patients' bodies that could predict how well they respond to immunotherapy. Ultimately, the trial aims to improve treatment strategies for NSCLC patients after surgery by better understanding the role of immunotherapy.

Resected:

Some patients have a tumor that is “resectable,” which means that it is able to be removed with surgery.

Immunotherapy:

The immune system helps fight cancer by sending the body's defense (immune) system to kill the cancer cells. Immunotherapy drugs target cancer cells to prevent them from multiplying and growing.

Therapy given after surgery for cancer

Adjuvant therapy:

Site:

Einstein

NCT Number:

NCT04267848

NCI-2021-06578

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab plusChemotherapy in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

There are two medical studies happening in this phase 2 trial. One is looking at a drug called Adagrasib by itself and with another